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Abstract 
Introduction. The introduction of omics data and advances in technologies involved in clinical treatment has led 
to a broad range of approaches to represent clinical information. Within this context, patient stratification across 
health institutions due to omic profiling presents a complex scenario to carry out multi-center clinical trials. 
Methods. This paper presents a standards-based approach to ensure semantic integration required to facilitate the 
analysis of clinico-genomic clinical trials. To ensure interoperability across different institutions, we have 
developed a Semantic Interoperability Layer (SIL) to facilitate homogeneous access to clinical and genetic 
information, based on different well-established biomedical standards and following International Health (IHE) 
recommendations. 
Results. The SIL has shown suitability for integrating biomedical knowledge and technologies to match the latest 
clinical advances in healthcare and the use of genomic information. This genomic data integration in the SIL has 
been tested with a diagnostic classifier tool that takes advantage of harmonized multi-center clinico-genomic 
data for training statistical predictive models. 
Conclusions. The SIL has been adopted in national and international research initiatives, such as the EURECA-
EU research project and the CIMED collaborative Spanish project, where the proposed solution has been applied 
and evaluated by clinical experts focused on clinico-genomic studies. 
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1. Introduction 
Clinical trial complexity is dramatically increasing as new genetic and molecular variables are 
gathered in clinical settings [1]. Due to the costs of such clinical studies and challenges for recruiting 
trial cohorts, they often involve multiple clinical institutions [2]. New data management methods are 
therefore required by clinical users and investigators from institutions involved in multi-center 
clinical research [3]. In most cases, researchers need to know the different data representations of the 
institutions participating in the study and significant manual data management is required [4]. To 
facilitate certain processes required to achieve semantic integration from heterogeneous sources in the 
area (e.g., clinical trial management systems, electronic health records or laboratory systems, among 
others) (semi-) automatic methods have been recently addressed by international initiatives [5]. 
 
Several efforts have recently focused on facilitating communication and exchange of information 
between clinical systems by using biomedical standards [6]. In general, interoperability initiatives 
provide an underlying data model for different areas. Examples of these initiatives are, to mention a 
few relevant examples, the Observational Medical Outcomes Partnership (OMOP) [7], Integrating 
Biology and the Bedside (i2b2) [8], the HL7 Reference Information Model (RIM) [9], Fast 
Healthcare Interoperability Resources (FHIR) [10], Integrating the Healthcare Enterprise (IHE) [11] 
or PCORnet [12]. These initiatives have been developed with the objective of obtaining valuable 
results in the clinical research area. Few translational research platforms have actually exploited the 
benefits of the analysis and interaction of interoperability models with genetic information and 
related terminologies [13], i.e. tranSMART platform that is based on i2b2 [14]. 
 
Clinical terminologies have been historically used in medicine to classify and categorize diseases. 
One of the most relevant terminologies is SNOMED-CT (Systematized Nomenclature of Medicine - 
Clinical Terms) [15]. SNOMED-CT is a general purpose clinical vocabulary distributed by The 
International Health Terminology Standards Development Organization (IHTSDO), with over 400 
thousands concepts, 1 million of descriptors and more than 1 million of relationships between them. 
While SNOMED-CT provides broad coverage, there are other terminologies oriented to more 
specific clinical areas. Logical Observation Identifiers Names and Codes (LOINC) [16], developed 
by the Regenstrief Institute in Indiana, USA, is a clinical terminology for identifying laboratory and 
clinical test results. 
 
In the context of breast cancer research, recent studies show that more than 5% of breast cancer 
patients might be hereditary [17], caused by gene information inherited from their families' relatives. 
“All-purpose” terminologies such as SNOMED-CT frequently do not provide the highest coverage 
for this specific domain. In this area, terminologies such as the HUGO Gene Nomenclature 
Committee (HGNC) [18] contain only genetic concepts. HUGO is an international classification of 
the human gene nomenclature, and an open access database containing more than 33,000 gene names 
and symbols at the time of writing. The majority of these items are protein-coding genes, but they 
also contain pseudogenes, non-coding RNAs, phenotypes and genomic features. 
 
With an increasing focus on genomics, in last years the number of translational biomedicine 
solutions has significantly increased. Different approaches intend to exploit the availability of omic 
data correlated with clinical data to enhance prevention, diagnosis, and therapies [19][20]. 
Standardization initiatives in biomedicine such as tranSMART [14], HL7 in standard v3 [21], HL7 
FHIR [22] and CDISC [23] are actively working in translational biomedicine. I.e. CDISC has 
delivered the Study Data Tabulation Model (STDM) [24] for representing the clinical domain; 
CDISC also propose an implementation guide for pharmacogenomics and pharmacogenetics 
(STDMIG-PGx) [25], defining relations of biospecimen and genetics-related data. Research projects 
such as the cancer translational research informatics platform (caTrip) [26] or BioShare [27], have 
proposed the exploitation of BioBank data together with electronic health records (EHR) data on 
breast cancer, providing insights on the viability of implementing translational platforms. Electronic 
Medical Records and Genomics Network (eMERGE) has been created to plan the integration of 
genomic data into the next-generation of EHRs [28] in a project from 2007 to 2019. eMERGE 
consider three different strategies to genomic and clinical data. One approach is to store each 
laboratory genetic result into the EHR system, introducing significant storage requirements for 
multiple tests looking at a broad range of polymorphisms. The second approach is to generate 
interpretation of the genomic information at a single point and store it in the EHR assuming the 
degree of information loss vs. performance improvement. And the third one is linking the original 
data with an external genetic resource through the EHR system without any loss of genetic 
information. 
 
We describe our proposed Semantic Interoperability Layer (SIL), and selected examples of its 
applications within international research projects: EURECA (Enabling information re-use by linking 
clinical Research and Care)[29] and CIMED (Collaborative Project on Medical Informatics). The 
objective is to investigate if such standards-based approach can be used to integrate all the genomic 
information support (similar to eMERGE Project) for the analysis of its interactions in breast cancer 
studies and diagnostic classifier analysis. This Semantic Interoperability Layer uses standard 
terminologies as a vehicle for addressing two main challenges in multi-centric interoperability: 
harmonizing heterogeneities from different data sources as well as for integrating omic and clinical 
data. 
2. Materials and methods 
To homogenize common information across different clinical settings, such as clinical trial 
management (CTMS) systems, electronic health records (EHR), laboratory information management 
systems (LIMS) and others, in this work we propose a standard-based SIL including one common 
information model (CIM) and a set of services as homogenous endpoints to access data. As shown in 
Fig. 1, the proposed SIL is defined by the interaction between the CIM and services for data access. 
The CIM is composed of three main components: (i) the common data model (CDM), (ii) the core 
dataset (terminologies) and (iii) the linking between them (terminology binding). The SIL was 
designed as the basis for software services and tools developed within the project, which are focused 
on enhancing clinical research with genetic information. 
 
 
 
Fig. 1. Interaction diagram of SIL components. 
To analyze the interaction of breast cancer gene expressions with clinical data, a set of services 
for data retrieval were defined within the SIL. These services provided uniform access to data stored 
in the SIL, exploiting semantic and abstraction capabilities of the CIM. The core dataset integrates 
terminologies such as SNOMED-CT, HGNC and LOINC for covering the clinical scenario domain 
[30]. The CDM is a HL7 RIM-based structure required to homogenize data models of information 
systems from different institutions. Finally, a binding solution for linking the concepts from clinical 
terminologies to the corresponding CDM classes has been developed. In this work, the SIL provides a 
standard infrastructure to integrate clinical and genetic information exploited by diagnostic 
classifiers. 
  
2.1. Common information model support for genetic information 
2.1.1. Core dataset extension with genetic information 
 
In general, biomedical data integration requires the use of terminologies to annotate data sources 
and facilitate the integration of data from heterogeneous sources. After the analysis of data sources of 
different projects, the approach adopted to create the core dataset was to select complementary 
subsets of widely used terminologies and ontologies. The core dataset is mainly based on SNOMED-
CT but it was extended with other domain specific terminologies, such as LOINC for laboratory tests 
and HGNC for gene names. Selected terminologies have been integrated together into a Web 
Ontology Language (OWL) file and loaded into a Sesame [31] Server. The Core Dataset is therefore 
available through a common SPARQL endpoint for the rest of the SIL components. 
 
When harmonizing data with terms coded in other terminologies, such as ICD [32], Gene 
Ontology [33] and the NCI thesaurus [34], original concepts are annotated with Core Dataset 
concepts. However, selected concepts for annotating original data to a core dataset may lack certain 
information contained in the original concept. For this reason, the semantic layer can store both the 
original and the annotated code. The annotation process strongly depends on each data source, from 
original data sources structured with coded values where automatic translations using UMLS are 
possible, to free-text data sources where annotation is a more laborious process that could be 
enhanced using NLP techniques [30]. In any case, after the annotation process, a manual validation of 
mapped terms by a domain expert is required. 
 
The main goal of the Core Dataset is to provide a comprehensive terminology to cover the source 
data. SNOMED-CT covered nearly all clinical concepts from the EURECA project, but lacked 
specific concepts related to radiotherapy and genes. For allowing the mapping of those concepts not 
covered, LOINC and the HGNC are used in combination with SNOMED-CT. 
2.1.2. Common data model (CDM) 
 
The CDM is the structure responsible of representing and storing data from clinical institutions. 
To facilitate the integration of legacy systems that may use built-in or open source, a relational 
database based on HL7 Reference Information Model (RIM) was developed. Different technologies 
were analyzed to implement the common data model [35], selecting a relational database due to 
performance for large patient datasets. To support semantic querying through SPARQL, morph 
R2RML [36] was used for mapping common data model implemented relational schema to a virtual 
ontology. SPARQL can be then executed to retrieve the required data from the underlying relational 
database. 
2.1.3. Terminology binding of clinical and genetic information 
 
The Terminology Binding component defines the mapping between Core Dataset concepts and 
the CDM. It defines in which fields of the CDM, each concept from the core dataset could be stored 
[37]. 
 
While HL7 RIM is able to represent a wide domain of clinical information, it also allows storing 
the same piece of information in different ways. As the same concept may have different contexts, 
they can be stored in different CDM attributes. For this reason, a core dataset automatic 
normalization process to homogenize the representation of these concepts was developed. This 
normalization process uses SNOMED Normal Form [38] for decomposing complex concepts into a 
combination of atomic concepts. Storing only normalized SNOMED-CT concepts in the data model 
simplifies the binding between concepts and the RIM following IHE recommendations [39]. 
 
Binding information has been attached to each Core Dataset concept, linking to its corresponding 
common data model attribute by including annotations in the Core Dataset OWL file. For this 
purpose IHE and the TermInfo project recommendations have been used, which associate some 
concepts of SNOMED-CT to an HL7 RIM class. The RIM class association is propagated, from 
SNOMED-CT concepts where it is defined, to all their subconcepts, labeling them with the same 
RIM class. Other terminologies included in Core Dataset are also linked to RIM classes and 
attributes, but in this case the linking is easier than in SNOMED-CT case. All LOINC concepts 
correspond to code attribute of HL7 RIM Observation; and gene names in HGNC has been bound to 
code attribute of the HL7 RIM Entity class. 
2.2. Services for data load & retrieval 
As depicted in Fig. 1, a set of services for accessing the CDM and core dataset knowledge were 
developed. The SIL solution is based on SOAP architecture through HTTPS communication protocol 
ensuring the security of the services. These services allow the abstraction of the CDM schema 
representation relying only in the Core Dataset concepts and a clinical context. Using the Query 
Builder Service it is possible to obtain necessary information to build a query of any concept from the 
core dataset, by providing only that concept. The Core Dataset service contains a set of methods to 
query the semantic repository of the terminology and to normalize core dataset expressions into a 
more generic concepts. 
 
A standardized service for querying and populating the CIM is required to seamlessly retrieve 
data across applications. To provide semantic reasoning methods supported by the core dataset, a 
CIM Access service and a Data Push service were also developed. The CIM Access Service provides 
an SPARQL query endpoint to retrieve HL7 RIM-based data. This allows use of hierarchical 
information over normalized data stored in the CDM by using Core Dataset relationships [40]. 
 
The Data Push service stores information from different data sources into the CIM representation. 
This service uses the normalization method of the Core Dataset service to provide a homogeneous 
data representation. By using the Data Push service, the CIM can represent clinical information in the 
original and normalized form to ensure that no information is lost in the process. 
2.3. Gene expression data integration 
Datasets integrated within the EURECA SIL have been collected from clinical EHR systems, 
LIMS and CTMS integrating data of patients from clinical trials. Gene expression data extracted from 
clinical samples is used to explore potential interactions between clinical and genomic data. 
 
As recommended by HL7 clinical genomics work group, genomic data could be hardly modelled 
as acts in the RIM [21]. Additionally HL7 FHIR genomics group has defined specific FHIR genomic 
resources [22] using SNOMED-CT and HGNC for modelling genetic tests. The authors decided to 
store gene expression data maintaining its original format in the CDM, by using a combination of 
RIM objects accordingly to the previously defined Core Dataset. A terminology guided approach has 
been applied, where every genomic observation in the CDM is completely defined by its field Act 
code. 
 
As shown in Fig. 2, patient data were annotated with Core Dataset concepts and stored in the 
CDM. Concretely, gene expression data were annotated with HGNC concepts linked to a HL7 RIM 
observation defined by the Genetic test SNOMED concept. 
  
 
 
 
Fig. 2. Example of the Oxford Structured Breast Cancer dataset in CDM. 
The integration of gene expression data in the SIL was a crucial task to facilitate the use of 
diagnostic classifier tools in the EURECA project. The focus of the diagnostic classifier is in 
assisting physicians in the process of diagnosing individual patients. This assistance involves tools 
that are trained to define diagnostic clusters using a training set of datasets. These models are then 
evaluated using validation datasets to assess whether new patients are clustered in the correct 
diagnostic category. The diagnostic classifier required input datasets that are heterogeneous for the 
clinical characteristics and the gene expression patterns; the algorithm is unable to distinguish 
diagnostic subgroups of patients when there is no variety in patient characteristics, for example if 
there is only one specific subtype of cancer present in the data. To demonstrate the suitability of the 
proposed approach, such heterogeneous datasets, including clinical and genomic data, were retrieved 
using the standard-based SIL to bind clinical and genetic information. In the Results Section the 
complete workflow is described, from harmonized clinical and genomic data retrieved from the SIL, 
to the results of the diagnostic classifier tool. 
3. Results 
Several datasets that had been shared under the EURECA project were stored and homogenized 
using the proposed SIL during the EURECA project. Especially relevant for genetic data integration 
was the Oxford dataset within the project, a retrospective data collection from 219 patients from the 
Oxford Structured Breast Cancer dataset [41]. This dataset is composed of clinical data of patients 
collected from EHR systems and also gene expression data (log2 measurement of mRNA abundance) 
of 16,814 human genes for every patient, measured using Illumina microarray. These measurements 
were extracted from biopsies of breast tumor tissues. Tumor specific gene expression is highly 
variable within the same tumor and very different from the expression of the patient's normal tissue. 
 
Genetic test data represents 6% of observational data and every genetic observation of a patient in 
the CDM, containing 16 K gene measurements. Although genetic test data represent a small 
percentage of observations (following HL7 representation depicted in Fig. 2), it contains a large 
quantity of information. Appendix A describes the concepts used from core dataset terminologies to 
represent data sources within the CDM containing the Oxford dataset. 
 
We used 219 patients from Oxford with clinical and gene expression data for the diagnostic 
classifier use case. A consensus clustering method (ConsensusClusterPlus) was used to group the 
patients based on the expression of all genes [42]. In this method, visualising the Consensus 
Cumulative Distribution Function (CDF) for a range of number of clusters can be used to determine 
the optimal number of clusters. Although the clustering process is unsupervised, which means that 
the outcome value was not taken into account while clustering, distant recurrence free survival 
(DRFS) after 10 years of follow-up was used to test if the found clusters were prognostic, i.e., have 
an association with patient outcome. In Table A1 clinical and genomic variables present in the dataset 
are described. 
 
To process data coming from the SIL into R scripts, data was retrieved using SPARQL queries 
and then transformed it into raw dataset (in csv format). A procedure has been developed to process 
and analyse data for the diagnostic classifier scenario. This procedure is divided in five steps: (i) data 
acquisition from SIL, (ii) dataset translation, (iii) pre-processing, (iv) analysis execution, and, (v) 
output display. 
 
(i) Data acquisition from SIL. As every diagnosis or procedure of a patient is stored as one HL7 
act – implying often several RIM objects – inside the CDM, and coded using concepts from 
CD, each variable required for the diagnostic classifier tool is obtained using one query built 
by Query Builder Service and the CIM Access Service from the SIL. Thanks to the abstraction 
provided by the SIL Query Builder Service, we can obtain a functional SPARQL query by 
asking for one (SNOMED-CT) concept. For example if we utilize ‘Node category finding 
(385382003)’ concept, the following SPARQL is returned from SIL Query Builder Service: 
 
This query allows retrieval of all HL7 acts stored in the CDM that are coded using the code 
385382003 or any of its subsumptions, which are concrete values for the N status finding: N0, N1, 
N2 and N3 Category concepts. Afterwards, when the SPARQL query is executed through the CIM 
Access Service, it retrieves results in XML format containing all observations of N status categories 
for all patients in the CD. The results obtained contain all attributes present in SPARQL query, and 
each row is an occurrence of an ‘N status’ measurement for a given patient as shown in Table 1. 
Table 1. Example resultset for node category finding SPARQL query. 
act_id Code Title patientId birthTime effectiveTime 
      
007c36f9- … 53623008 N1 category 63paseqzdwgq … 1936-10-30 T00:00:00.0 1990-12-08 T00:00:00.0 
024bcfa6- … 62455006 N0 category 55af4sm4yuwt … 1941-07-03 T00:00:00.0 1992-07-03 T00:00:00.0 
      
 
 
  
Similar to clinical data observations (like ‘Node category finding’), gene expression data was 
modelled using HL7 recommendations. For this purpose the SIL Query Builder Service is invoked 
using the code ‘Genetic test (405824009)’, obtaining the SPARQL query: 
 
The Query Builder service returns this SPARQL query that is capable of retrieving gene 
expressions data stored in the SIL. Also in this case, presented in Table 2, each row of the result set 
corresponds to the gene expressions data of one patient. 
Table 2. Example result set for node category finding SPARQL query. 
act_id Code title patientId birthTime Effective Time Value 
       
007c36f9- 
… 
405824009 Genetic 
test 
63paseqzdwgq 
… 
1936-10-30 
T00:00:00.0 
1990-12-08 
T00:00:00.0 
ENSG00000091482, 
ENSG00000144834, 
ENSG00000187522, 
ENSG00000185222, 
ENSG00000008324 … 
007c36f9- 
… 
405824009 Genetic 
test 
63paseqzdwgq 
… 
1936-10-30 
T00:00:00.0 
1990-12-08 
T00:00:00.0 
ENSG00000144834, 
ENSG00000187522, 
ENSG00000008324, 
ENSG00000128510, 
ENSG00000169241,…, 
       
 
Then, for each input variable in diagnostic classifier one different query has to be executed. 
Afterwards, different results obtained for each variable are combined, building a standardized cohort 
containing all relevant columns from each SPARQL query. 
  
(ii) Dataset translation: An intermediate step is performed to produce a dataset accepted by R 
scripts. SNOMED-CT codes are converted to R readable names and numerical values for 
clinical data. In this step gene expressions data is transformed by splitting it in different 
columns of the dataset. 
 
(iii) Pre-processing: The top X genes (default X = 500) with highest standard deviation for gene 
expression are selected, patients without outcome are excluded, missing data is inputted using 
expectation maximization imputation and clinical variables are categorized if necessary. 
 
(iv) Analysis execution: A consensus clustering is applied using the R-package 
ConsensusClusterPlus (v1.24.0). 
 
(v) Output display: Optimization of the number of clusters parameters and the clustering 
heatmap showing clustered gene expression values, assigned patient clusters and the 
prognostic values of these clusters. 
 
The most important output from the diagnostic classifier is the clustering heatmap, which is 
depicted in Fig. 3. This heatmap shows the mRNA expression (normalised by z-score) of every gene 
for all the patients. Both axes of the figure are clustered using hierarchical clustering, resulting in 
clustering of similar patients in genes on a gene expression level. Above the heatmap it can be 
observed which patients belong to which clusters based on the consensus clustering described above, 
for a range of number of clusters (in this case k = 2 to 7). On top of the figure the status of the 
categorized clinical variables is depicted, to identify any correlation between gene expression clusters 
and clinical data. In the selected dataset, we can clearly see 3 clusters (red, blue and green) and the 
possibility to identify outlier patients that consistently form a cluster on their own. If we take the case 
of five clusters, which was sufficient according to the CDF visualisation, we can check whether the 
distant recurrence free survival is also different in these clusters (Fig. 4). Kaplan-Meier curves are 
plotted for distant-recurrence free survival for each of the clusters from consensus clustering with the 
selected number of clusters. 
  
 
 
 
Fig. 3. Heatmap of gene expression (z-score), with hierarchical clustering in both directions. 
Clustered patients are indicated based on consensus clustering for k = 2 to 7 with the provided 
colour legend and the categorical value of the clinical variables age, tumor size (TSize), nodal 
status (Nstatus), menopause status, radiotherapy given (RT) and chemotherapy given (Chemo) 
are provided at the top. 
  
 
 
 
Fig. 4. Kaplan-Meier curves for distant-recurrence free survival 
(DRFS) for each of the clusters from consensus clustering with 
selected number of clusters is 5. At the bottom is depicted how 
many patients are still event-free at the indicated time points. The 
survival curves are not significantly distinct as is tested using 
logrank test. 
As observed in this section, the utilization of the SIL allows storing data from heterogeneous 
datasets harmonizing clinical and genomic data. It also facilitates the access to clinical and genomic 
information for execution of biomedical tools. SIL provides an unique and standardized interface to 
data, therefore, tools' developers do not need to implement connectors for different systems, and data 
managers do not need to navigate into different information systems to collect data for tools 
execution. 
4. Conclusions 
This article presented a Standard-based SIL approach to integrate and facilitate the analysis of 
clinical and genomic data interaction in breast cancer patients. The proposed SIL allows 
homogeneous representation and access of patient data seamlessly facilitating the development of 
generic tools. This approach has been evaluated by experts within pilots and workshops during the 
EURECA and CIMED projects, and by European Commission experts in live demonstrations during 
project reviews. The proposed approach was successfully extended to other domains during the 
EURECA project: lung cancer, colorectal cancer, febrile neutropenia [29]. 
 
In this work, the SIL has been applied to store comprehensive genetic tests within the same 
structure that clinical related information is stored. The proposed integration process has been 
evaluated with real data from a breast cancer dataset from the Oncology Department of the University 
of Oxford. In this dataset, we achieved storage of information recorded from 219 patients during a 
clinical trial. The main contribution was to integrate the complex results of genetic tests performed on 
patients in the study, facilitating the access for bioinformatics tools that require genomic information 
for their execution. 
 
The SIL was successfully tested for running the diagnostic classifier tool over the dataset stored in 
the CDM. The proposed method solves effectively most heterogeneities and integration challenges of 
current post-genomic clinical trial scenarios. Results show the semantic capabilities of the proposed 
approach, exploiting knowledge inferred from the different biomedical terminologies in the core 
dataset. 
  
Author contributions 
Raul Alonso-Calvo and Sergio Paraiso-Medina wrote the paper; Raul Alonso-Calvo, Sergio Paraiso-Medina, and 
David Perez-Rey conceived and designed the experiments; Sergio Paraiso-Medina and Raul Alonso-Calvo 
performed the experiments; Sheng Yu, Ruud Van Stiphout, Marian Taylor and Francesca Buffa provided the 
data and contributed in diagnostic classifier experiment and analysis tools; Sergio Paraiso-Medina, Enrique 
Alonso-Oset and Carlos Fernandez-Lozano analyzed the data; Victor Maojo and Alejandro Pazos reviewed and 
validated the methodology proposed. 
Conflicts of interest 
The authors declare no conflict of interest. 
Author contributions 
Raul Alonso-Calvo and Sergio Paraiso-Medina wrote the paper; Raul Alonso-Calvo, Sergio Paraiso-Medina, and 
David Perez-Rey conceived and designed the experiments; Sergio Paraiso-Medina and Raul Alonso-Calvo 
performed the experiments; Sheng Yu, Ruud Van Stiphout, Marian Taylor and Francesca Buffa provided the 
data and contributed in diagnostic classifier experiment and analysis tools; Sergio Paraiso-Medina, Enrique 
Alonso-Oset and Carlos Fernandez-Lozano analyzed the data; Victor Maojo and Alejandro Pazos reviewed and 
validated the methodology proposed. 
Acknowledgments 
This work is supported by EURECA project funded by the European Commission [grant number FP7-ICT-2011-
5.3- 288048]; and the “Collaborative Project on Medical Informatics (CIMED)” funded by the Carlos III Health 
Institute from the Spanish National plan for Scientific and Technical Research and Innovation 2013–2016 and 
the European Regional Development Funds (FEDER) [grant numbers PI13/02020, PI13/00280]. 
  
Appendix A. Data characterization of the clinico-genomic data source integrated 
Table A.1. Core Dataset concepts present in Oxford breast cancer dataset within CDM. 
CD Concept 
Code 
CD Label 
% Patients incl. 
concept 
% of total data 
    
443527007 Number of lymph nodes involved by malignant neoplasm (observable 
entity) 
100% 6,10% 
444025001 Number of lymph nodes examined (observable entity) 100% 6,10% 
263605001 Tumor size (observable entity) 100% 6,10% 
405824009 Genetic test 98,63% 6,02% 
106221001 Genetic finding (finding) 95,89% 5,85% 
108290001 Radiation oncology AND/OR radiotherapy (procedure) 84,02% 5,12% 
178294003 Axillary lymph nodes sampling (procedure) 77,17% 4,71% 
82711006 Infiltrating duct carcinoma (morphologic abnormality) 74,43% 4,54% 
289903006 Menopause present (finding) 67,12% 4,09% 
64368001 Partial mastectomy (procedure) 66,67% 4,07% 
309542002 Endocrine therapy (procedure) 58,45% 3,56% 
62455006 N0 category (finding) 57,99% 3,54% 
161917009 Recurrence of problem (finding) 56,16% 3,43% 
399879007 Malignant epithelial neoplasm - category (morphologic abnormality) 56,16% 3,43% 
399350006 Under follow-up (finding) 51,14% 3,12% 
30893008 M0 category (finding) 51,14% 3,12% 
14799000 Neoplasm, metastatic (morphologic abnormality) 48,86% 2,98% 
445150007 Surviving free of recurrence of neoplastic disease (finding) 43,84% 2,67% 
53623008 N1 category (finding) 42,01% 2,56% 
1663004 G2 grade (finding) 41,55% 2,53% 
289904000 Menopause absent (finding) 32,88% 2,01% 
61026006 G3 grade (finding) 31,05% 1,89% 
367336001 Chemotherapy (procedure) 25,11% 1,53% 
172043006 Simple mastectomy (procedure) 23,74% 1,45% 
54102005 G1 grade (finding) 19,18% 1,17% 
89740008 Lobular carcinoma (morphologic abnormality) 12,33% 0,75% 
444057000 Infiltrating carcinoma with ductal and lobular features (morphologic 
abnormality) 
9,13% 0,56% 
122548005 Biopsy of breast (procedure) 7,31% 0,45% 
234254000 Excision of axillary lymph nodes group (procedure) 1,83% 0,11% 
392021009 Lumpectomy of breast (procedure) 1,83% 0,11% 
4631006 Tubular adenocarcinoma (morphologic abnormality) 1,83% 0,11% 
32913002 Medullary carcinoma (morphologic abnormality) 1,37% 0,08% 
72495009 Mucinous adenocarcinoma (morphologic abnormality) 0,91% 0,06% 
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